Skip to main content
. Author manuscript; available in PMC: 2010 Aug 15.
Published in final edited form as: J Immunol. 2009 Jul 22;183(4):2365–2372. doi: 10.4049/jimmunol.0900721

Figure 6. ChNKG2D T cells require host cell-derived perforin and IFN γ for in vivo efficacy.

Figure 6

ID8-GFP cells were injected i.p. into (A) B6 or B6.IFNγ−/− mice or (B) B6, B6.Perforin−/−, or B6.GM-CSF−/− mice. After seven days, mice received wtNKG2D (WT) or chNKG2D (CH) T cells i.p. Tumor burden was determined after 8 weeks by measuring the absolute number of GFP+ cells in the peritoneal wash or number of solid tumors on the peritoneum. Each data point represents an individual and the average of each group is shown. Data are from at least two separate experiments. * p<0.05- compared with WT T cell treatment. § p<0.05, compared with CH T cell treatment.